Teva Pharmaceutical (TEVA) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical (NASDAQ: TEVA) reported Q2 EPS of $1.10, $0.01 better than the analyst estimate of $1.09. Revenue for the quarter came in at $4.21 billion versus the consensus estimate of $4.24 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
- Ennis (EBF) Reports In-Line Q1 EPS
- Kroger meets earnings expectations, revenue tops estimates
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
